Contributing factors of diabetes mellitus among patients with gout (results of the long-term prospective study)

It is assumed that the risk of developing type 2 diabetes mellitus (T2DM) in patients with gout is influenced by both generally accepted risk factors and factors related to gout.

Objective. To evaluate the impact of various risk factors for T2DM in patients with gout.

Material and methods. 444 patients (49 women, 395 men) ≥18 years old with gout and without DM were included. Duration of observation was 5.66 [2.69; 7.64] g. To identify factors associated with the risk of developing T2DM, multivariate logistic regression was used, which included: sex; T2DM in relatives; insufficient physical activity; unbalanced diet; age ≥45 years; ≥4 attacks per year; presence of tophi; BMI≥30 kg/m2 ; allopurinol, febuxostat, glucocorticoids, diuretics, metformin, colchicine; GFR<60 ml/min/1.73 m2 ; serum uric acid level (sUA) ≥420 μmol/l and ≥480 μmol/l. Results. T2DM developed in 108 (24.3%) patients. According to the multivariate model, the presence of ≥4 attacks of arthritis per year increased the risk of T2DM (OR=5.23; 95% CI: 2.98–9.19; p=0.0001); presence of tophi (OR=2.61; 95% CI: 1.50–4.54; p=0.001); sUA≥480 μmol/l (OR=2.26; 95% CI: 1.02–5.00; p=0.144), diuretics (OR=2.35; 95% CI: 1.19–4.64; p=0.014). Febuxostat (OR=0.31; 95% CI: 0.11–0.84; p=0.022) and metformin (OR=0.49; 95% CI: 0.21–1.16; p=0.107) reduced the risk of developing T2DM. Conclusion. Risk of T2DM in patients with gout is associated with high incidence of arthritis attacks, MK≥480 μmol/l, hypertension, diuretic use, and febuxostat and metformin reduces risk. Key words: gout, type 2 diabetes mellitus, uric acid>˂ 60 ml/min/1.73 m2 ; serum uric acid level (sUA) ≥420 μmol/l and ≥480 μmol/l.

Results. T2DM developed in 108 (24.3%) patients. According to the multivariate model, the presence of ≥4 attacks of arthritis per year increased the risk of T2DM (OR=5.23; 95% CI: 2.98–9.19; p=0.0001); presence of tophi (OR=2.61; 95% CI: 1.50–4.54; p=0.001); sUA≥480 μmol/l (OR=2.26; 95% CI: 1.02–5.00; p=0.144), diuretics (OR=2.35; 95% CI: 1.19–4.64; p=0.014). Febuxostat (OR=0.31; 95% CI: 0.11–0.84; p=0.022) and metformin (OR=0.49; 95% CI: 0.21–1.16; p=0.107) reduced the risk of developing T2DM.

Conclusion. Risk of T2DM in patients with gout is associated with high incidence of arthritis attacks, MK≥480 μmol/l, hypertension, diuretic use, and febuxostat and metformin reduces risk. 

1. Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21(4):21. doi: 10.1007/s11886-019-1107-y

2. Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2): 110-116. doi: 10.2174/1570161117666190405165151

3. Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med. 2017;15(1):131. doi: 10.1186/s12916-017-0901-x

4. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31(8):1582- 1587.

5. Menon A, Roddy E. Update on factors predisposing to gout. Int J Clin Rheumat. 2009;4:75-87. doi: 10.2217/17584272.4.1.75

6. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: A systematic review of the literature. Curr Opin Rheumatol. 2011;23(2):192-202. doi: 10. 1097/BOR.0b013e3283438e13

7. Rho YH, Lu N, Peloquin CE, Man A, Zhu Y, Zhang Y, et al. Independent impact of gout on the risk of diabetes mellitus among women and men: A population-based, BMI-matched cohort study. Ann Rheum Dis. 2016;75(1):91-95. doi: 10.1136/annrheumdis-2014-205827

8. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210-216. doi: 10.1097/BOR.0b013e32835d951e

9. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 2017;15(1):123. doi: 10.1186/s12916-017-0890-9

10. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607. doi: 10.2337/diab.37.12.1595

11. Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78(1):25-29. doi: 10.1210/jcem.78.1.8288709

12. King C, Lanaspa MA, Jensen T, Tolan DR, Sánchez-Lozada LG, Johnson RJ. Uric acid as a cause of the metabolic syndrome. Contrib Nephrol. 2018;192:88-102. doi: 10.1159/000484283

13. van der Schaft N, Brahimaj A, Wen KX, Franco OH, Dehghan A. The association between serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: The Rotterdam Study. PLoS One. 2017;12(6):e0179482. doi: 10.1371/journal. pone.0179482

14. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737-1742. doi: 10.2337/dc09-0288

15. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900. doi: 10.1002/art.1780200320

16. Alberti G. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1998–1999 International Diabetes Federation European Region. Exp Clin Endocrinol Diabetes. 1999;107(7):390-420.

17. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii,1-253.

18. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. doi: 10.1002/art.22466

19. Kowalski J, Krzemińska A, Banach M, Pawlicki L, ŚliwczyńskaRodziewicz D, Barylski M. The concentration of uric acid in patients with metabolic syndrome and cardiovascular diseases. Open Medicine. 2009;4(3):272-278. doi: 10.2478/s11536-009- 0026-5

20. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57(6):845-852. doi: 10.1016/j. metabol.2008.01.030

21. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47(10):1567-1570. doi: 10.1093/rheumatology/ken305

22. Kim SC, Liu J, Solomon DH. Risk of incident diabetes in patients with gout: A cohort study. Arthritis Rheumatol. 2015;67(1):273-280. doi: 10.1002/art.38918

23. Thottam GE, Krasnokutsky S, Pillinger MH. Gout and metabolic syndrome: A tangled web. Curr Rheumatol Rep. 2017;19(10):60. doi: 10.1007/s11926-017-0688-y

24. Li X, Meng X, Gao X, Pang X, Wang Y, Wu X, et al. Elevated serum xanthine oxidase activity is associated with the development of type 2 diabetes: A prospective cohort study. Diabetes Care. 2018;41(4):884-890. doi: 10.2337/dc17-1434

25. Sunagawa S, Shirakura T, Hokama N, Kozuka C, Yonamine M, Namba T, et al. Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: A pilot exploratory study. J Diabetes Investig. 2019;10(1):94-103. doi: 10.1111/jdi.12870

26. Lai HM, Chen CJ, Su BY, Chen YC, Yu SF, Yen JH, et al. Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences. Rheumatology (Oxford). 2012;51(4):715-720. doi: 10.1093/rheumatology/ker373

27. Sheliabina O, Elisеev M, Novikova A, Chikina M. POS1140. Risk factors for the development of diabetes mellitus in patients with gout according to a 6-year prospective follow-up study. Ann Rheum Dis. 2021;80(Suppl 1):849. doi: 10.1136/annrheumdis-2021-eular.3151

28. Елисеев МС, Барскова ВГ, Насонов ЕЛ, Зилов АВ, Насонова ВА. Особенности подагры, протекающей с сахарным диабетом II типа. Клиническая геронтология. 2005;11(4): 7-13. [Eliseev MS, Barskova VG, Nasonov EL, Zilov AV, Nasonova VA. Features of gout occurring with type II diabetes mellitus. Clinical Gerontology. 2005;11(4):7-13 (In Russ.)].

29. Oda E. Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population. Heart Vessels. 2014;29(4):496-503. doi: 10.1007/s00380-013-0386-2

30. Niskanen L, Laaksonen DE, Lindström J, Eriksson JG, KeinänenKiukaanniemi S, Ilanne-Parikka P, et al Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: The Finnish Diabetes Prevention Study. Diabetes Care. 2006;29(3):709-711. doi: 10.2337/diacare.29.03.06.dc05-1465

31. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978

32. Gunawardhana L, Becker MA, Whelton A, Hunt B, Castillo M, Saag K. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: Phase II placebo-controlled study. Arthritis Res Ther. 2018;20(1):99. doi: 10.1186/s13075-018-1593-0

33. Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Modern Rheumatology Journal. 2020;14(2):97-103 (In Russ.). doi: 10.14412/1996-7012-2020-2-97-103

34. Meng J, Li Y, Yuan X, Lu Y. Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. Rheumatol Int. 2017;37(2):299-303. doi: 10.1007/s00296-016-3612-2

35. Zoppini G, Targher G, Negri C, Stoico V, Perrone F, Muggeo M, et al. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care. 2009;32(9):1716-1720. doi: 10.2337/dc09-0625

36. Ito H, Abe M, Mifune M, Oshikiri K, Antoku S, Takeuchi Y, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One. 2011;6(11):e27817. doi: 10.1371/journal.pone.0027817

37. Afshari M, Larijani B, Rezaie A, Mojtahedi A, Zamani MJ, Astanehi-Asghari F, et al. Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, doubleblind placebo-controlled clinical trial. Biomed Pharmacother. 2004;58(10):546-550. doi: 10.1016/j.biopha.2004.09.012

38. Chang HW, Lin YW, Lin MH, Lan YC, Wang RY. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. PLoS One. 2019;14(1):e0210085. doi: 10.1371/journal.pone.0210085

39. Johnson RJ, Merriman T, Lanaspa MA. Causal or noncausal relationship of uric acid with diabetes. Diabetes. 2015;64(8):2720-2722. doi: 10.2337/db15-0532

40. Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924-929. doi: 10.1097/JIM.0000000000000242

41. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi: 10.1056/NEJMoa012512

42. Vazirpanah N, Ottria A, van der Linden M, Wichers CGK, Schuiveling M, van Lochem E, et al. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: A prelude to a new add-on therapy? Ann Rheum Dis. 2019;78(5):663-671. doi: 10.1136/annrheumdis-2018-214656

43. Barskova VG, Eliseev MS, Kudaeva FM, Aleksandrova EN, Volkov AV, Nasonova VA, et al. Effect of metformine on the clinical course of gout and insulin resistance. Clinical Medicine. 2009;87(7):41-46 (In Russ.).

44. Salvatore T, Pafundi PC, Galiero R, Gjeloshi K, Masini F, Acierno C, et al. Metformin: A potential therapeutic tool for rheumatologists. Pharmaceuticals (Basel). 2020;13(9):234. doi: 10.3390/ph13090234

45. Eliseev MS, Panevin TS, Zhelyabina OV, Nasonov EL. Advantages of the use of metformin in patients with impaired uric acid metabolism. Terapevticheskii arkhiv. 2021;93(5):628-634 (In Russ.). doi: 10.26442/00403660.2021.05.200795